New advances in peptide receptor radionuclide therapy

Journal of Nuclear Medicine

Volumn 43, Issue 5, 2002, Pages 617-620

  De Jong, Marion ^a   Krenning, Eric ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; BOMBESIN; CHOLECYSTOKININ; COPPER 64; GALLIUM 67; GALLIUM 68; GASTRIN; INDIUM 111; LUTETIUM; METAL DERIVATIVE; NEUROTENSIN; OCTREOTHER; OCTREOTIDE[3 TYROSINE]; PENTETATE INDIUM IN 111; RADIOISOTOPE; RADIOLIGAND; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ANEMIA; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW TOXICITY; BRONCHUS TUMOR; CANCER; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; ISOTOPE LABELING; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; NOTE; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

HUMANS; KIDNEY; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 0036251071     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (31)

1. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin
2. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide
3. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues
4. 111In-DTPA-D-Phe1]-octreotide: A case history
5. 111In-pentetreotide: State of the art and perspectives
6. 111In-pentetreotide: Initial observations and future directions
7. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
8. Yttrium-90 DOTATOC: First clinical results
9. 90Y-DOTATOC: Results of a phase I study
10. 90Y-DOTA-D-Phe1-Tyr3-octreotide
11. Safety and efficacy of [Y-90-DOTA, Tyr(3)]octreotide (Y-90-SMT487; OCTREOTHER™) peptide receptor radionuclide therapy (PRRT): Preliminary results of a phase-1 study
12. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
13. 90Y-DOTATOC
14. New trends in peptide receptor radioligands
15. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma
16. Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors: Preliminary results
17. Peptide receptor imaging and therapy
18. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue
19. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo
20. 90Y-labelled analogue
21. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somalostatin radiotracers selected for scintigraphic and radiotherapeutic use
22. Amino acids infusion for renal protection during radiolabeled peptide therapy: Comparison between different infusion regimens
23. Metabolic effects of amino acids solutions infused for renal radioprotection
24. Effective and safe inhibition of renal uptake of radiolabeled peptides by combined lysine and arginine infusion
25. 0]octreolide in patients
26. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
27. 177Lu-DOTA(0), Tyr3] octreotate for somatostalin receptor-targeted radionuclide therapy
28. Tumor response after [(90)Y-DOTA(0), Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size
29. 90Y-SMT 487) eradicates experimental rat pancreatic cancer: 20948 Tumours
30. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides
31. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review